CN101912394A - 一种用于治疗凝血障碍出血的药物组合物及其用途和治疗方法 - Google Patents
一种用于治疗凝血障碍出血的药物组合物及其用途和治疗方法 Download PDFInfo
- Publication number
- CN101912394A CN101912394A CN2010102484519A CN201010248451A CN101912394A CN 101912394 A CN101912394 A CN 101912394A CN 2010102484519 A CN2010102484519 A CN 2010102484519A CN 201010248451 A CN201010248451 A CN 201010248451A CN 101912394 A CN101912394 A CN 101912394A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- patient
- pharmaceutical composition
- hemorrhage
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000032843 Hemorrhage Diseases 0.000 title claims abstract description 43
- 208000015294 blood coagulation disease Diseases 0.000 title claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 6
- 206010053567 Coagulopathies Diseases 0.000 title abstract 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 39
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003104 ornithine Drugs 0.000 claims abstract description 21
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 20
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 18
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 16
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004475 Arginine Substances 0.000 claims abstract description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 10
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000007924 injection Substances 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- -1 VitB12 Chemical compound 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 239000004473 Threonine Substances 0.000 claims description 12
- 230000003203 everyday effect Effects 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 12
- 235000002374 tyrosine Nutrition 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 235000004400 serine Nutrition 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 235000018417 cysteine Nutrition 0.000 claims description 10
- 239000004474 valine Substances 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000008354 sodium chloride injection Substances 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 229940055726 pantothenic acid Drugs 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 abstract description 15
- 230000004064 dysfunction Effects 0.000 abstract description 9
- 208000028399 Critical Illness Diseases 0.000 abstract description 5
- 208000010718 Multiple Organ Failure Diseases 0.000 description 23
- 229960005261 aspartic acid Drugs 0.000 description 16
- 230000015271 coagulation Effects 0.000 description 15
- 238000005345 coagulation Methods 0.000 description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108090000190 Thrombin Proteins 0.000 description 10
- 229960001153 serine Drugs 0.000 description 10
- 229960002898 threonine Drugs 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 238000011443 conventional therapy Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 108010073385 Fibrin Proteins 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108010014173 Factor X Proteins 0.000 description 6
- 108010074864 Factor XI Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108010073651 fibrinmonomer Proteins 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- 102100030563 Coagulation factor XI Human genes 0.000 description 3
- 108010023321 Factor VII Proteins 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 230000000025 haemostatic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 208000035992 Postmortem Changes Diseases 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 210000005096 hematological system Anatomy 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003547 Asterixis Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000002350 fibrinopeptide Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于危重病人急救治疗领域,涉及一种用于治疗凝血障碍出血的药物组合物及其用途和治疗方法。该药物组合物每单位含有:L-鸟氨酸0.5~8g,天冬氨酸1~5g,精氨酸3~10g,维生素B63-10g。该药物组合物能有效治疗凝血功能异常而导致出血的患者,特别是危重患者的救治。
Description
技术领域
本发明属于危重病人急救治疗领域,涉及一种用于治疗凝血障碍出血的药物组合物及其用途和治疗因凝血障碍而出血的患者的方法。
背景技术
在严重创伤和感染情况下,血液系统常常会受到影响。在全身炎症反应综合征(systemic inflammatory response syndrome,SIRS)和多器官功能障碍(multiple organ dysfunction syndrome,MODS)的临床表现中,凝血系统的异常和功能障碍十分常见。文献报道,在多器官功能衰竭中血液系统受累占受累器官的前四位,个别文献报道占第二位。有时血液系统的异常成为病人死亡的主要原因和直接原因。在多器官功能障碍和衰竭时血液系统的异常改变主要分为有形成分的改变和凝血、止血功能的改变。凝血功能异常可以是疾病发生发展的必然结果,也可能是不适当治疗所诱发。在MODS时出现凝血功能异常而导致大出血的情况下,医生往往束手无策,绝大部分患者很快死亡。所以对此类濒死患者抢救的关键性技术研究十分重要。
正常情况下,机体的凝血过程通常分为内源性途径、外源性途径和共同途径。
内源性凝血途径是指参加的凝血因子全部来自血液(内源性)。当血管壁发生损伤,内皮下组织暴露,带负电荷的内皮下胶原纤维与凝血因子接触,因子Ⅻ即与之结合,在HK和PK的参与下被活化为XIIa。在不依赖Ca2+的条件下,因子XIIa将因子XI激活。在Ca2+的存在下,活化的XIa又激活了因子IX。单独的IXa激活因子X的效力相当低,它要与VIIIa结合形成1∶1的复合物,又称为因子X酶复合物。这一反应还必须有Ca2+和PL共同参与。即内源性凝血途径是指从因子Ⅻ激活,到因子X激活的过程。
外源性凝血途径是指参加的凝血因子并非全部存在于血液中,还有外来的凝血因子参与止血。这一过程是从组织因子暴露于血液而启动,到因子X被激活的过程。组织因子是存在于多种细胞质膜中的一种特异性跨膜蛋白。当组织损伤后,释放该因子,在Ca2+的参与下,它与因子VII一起形成1∶1复合物。因子VII与组织因子结合会很快被活化的因子X激活为VIIa。外源性凝血途径主要受组织因子途径抑制物(TFPI)调节。TFPI是存在于正常人血浆及血小板和血管内皮细胞中的一种糖蛋白。它通过与因子Xa或因子VIIa-组织因子-因子Xa结合形成复合物来抑制因子Xa或因子VIIa-组织因子的活性。另外,研究表明,内源凝血和外源凝血途径可以相互活化。
从因子X被激活至纤维蛋白形成,是内源、外源凝血的共同凝血途径。主要包括凝血酶生成和纤维蛋白形成两个阶段。
(1)凝血酶的生成:即因子Xa、因子Va在Ca2+和磷脂膜的存在下组成凝血酶原复合物,即凝血活酶,将凝血酶原转变为凝血酶。
(2)纤维蛋白形成:纤维蛋白原被凝血酶酶解为纤维蛋白单体,并交联形成稳定的纤维蛋白凝块,这一过程可分为三个阶段,纤维蛋白单体的生成,纤维蛋白单体的聚合,纤维蛋白的交联。凝血酶将带负电荷多的纤维蛋白肽A和肽B水解后除去,转变成纤维蛋白单体。纤维蛋白单体生成后,即以非共价键结合,形成纤维蛋白多聚体,又称为可溶性纤维蛋白。纤维蛋白生成后,可促使凝血酶对因子XIII的激活,在XIIIa与Ca2+的参与下,相邻的纤维蛋白发生快速共价交联,形成不溶的稳定的纤维蛋白凝块。
由于MODS的发病机制尚未完全阐明,临床治疗也一直未取得突破性进展,因此,MODS的病死率居高不下,特别是对MODS导致的昏迷、应急性溃疡大出血等,造成传统的凝血药物无法直接起作用,一般需采用高额费用的脏器支持体外循环辅助治疗。
据文献报道,凝血系统中有4个重要的凝血因子(因子II、因子V、因子Ⅶ和因子VIII)均有肝脏合成,在MODS下,高胆红素血症、转氨酶升高(ALT或AST)、LDH升高、低蛋白血症、凝血酶原时间延长、黄疸、扑翼样震颤;血小板计数<80000/ul或3天下降≥50%;指动脉血压≤90mmHg或平均动脉压≤70mmHg并伴有心动过速、心律失常、心脏骤停等。各种有害自由基的存在,加重脏器的破坏,特别是给肝脏带来严重的破坏,血氨浓度升高,代谢迟缓,关键酶及重要因子(4个重要凝血因子)的合成受阻,给MODS下的大出血的患者带来生命威胁。
发明内容
本发明的目的是提供一种用于治疗因凝血障碍而出血的药物组合物。
本发明的另一目的是提供上述药物组合物的用途。
本发明还有一个目的是提供一种运用上述药物组合物治疗因凝血障碍而出血患者的救治方法。
本发明作用机制:大剂量维生素B6是大脑及神经的保护剂,它也是天然的利尿剂,现已知有60多种酶需要维生素B6参与。配合维生素C,清除MODS产生的有害自由基,能迅速降低自由氧基对脏器的毒害。含有L-鸟氨酸、天冬氨酸、精氨酸的复方氨基酸能够提供为内源性凝血机制提供相应的底物,配合其中的高支链氨基酸,不仅能纠正支链氨基酸和芳香氨基酸代谢的失衡,还能抑制大脑中假性神经递质的形成,并能改善肝性脑病。L-鸟氨酸本身能够迅速穿透线粒体膜,在线粒体内通过代谢,携带一分子二氧化碳和一分子氨,转变为L-瓜氨酸,并又迅速穿过线粒体,配合L-天冬氨酸,即能迅速激活肝细胞内的尿素循环,将机体在MODS下产生的有害的二氧化碳及氨通过鸟氨酸代谢(尿素循环)排出体外,使得肝脏内酶代谢逐步恢复,4大重要凝血因子又得以产生,迅速恢复内源性凝血途径,配合常规治疗,能有效的治疗凝血障碍大出血濒死患者。
本发明的目的是通过下列技术方案实现的:
一种治疗凝血障碍出血的药物组合物,每单位该药物组合物中含有:L-鸟氨酸0.5~8g,天冬氨酸1~5g,精氨酸3~10g,维生素B63-10g。
所述的药物组合物,每单位该药物组合物中还含有下列物质中的一种或多种:异亮氨酸,亮氨酸,赖氨酸,蛋氨酸,苯丙氨酸,苏氨酸,色氨酸,缬氨酸,组氨酸,甘氨酸,丙氨酸,脯氨酸,天冬酰胺,半胱氨酸,谷氨酸,丝氨酸,酪氨酸,VitB1,VitB2,VitB3,泛酸,生物素,叶酸,VitB12,维生素C;
其中:氨基酸的用量分别是:异亮氨酸3~10g,亮氨酸5~15g,赖氨酸3~10g,蛋氨酸0.5~3g,苯丙氨酸0.5~3g,苏氨酸3~10g,色氨酸0.5~3g,缬氨酸5~15g,组氨酸3~8g,甘氨酸3~8g,丙氨酸3~10g,脯氨酸3~8g,天冬酰胺0.1~3g,半胱氨酸0.1~3g,谷氨酸3~10g,丝氨酸0.5~5g,酪氨酸0.1~3g;B族维生素的用量分别是:VitB11~2mg,VitB21~2mg,VitB310~20mg,泛酸3~5mg,生物素0.1~0.2mg,叶酸0.1~0.4mg,VitB122~6μg;维生素C 1-3g。
所述的药物组合物,该药物组合物还含有适量的5%葡萄糖氯化钠注射液或0.9%氯化钠注射液。
所述的药物组合物在制备治疗凝血障碍出血的药物中的应用。
一种因凝血障碍而出血的患者的救治方法,在适当时间内输注上述的药物组合物。
所述的治疗方法,轻度患者每日使用0.5~1单位上述药物组合物,静脉输液给药,30分钟-6小时输液完毕,连续使用1-9天;重度患者,每日使用0.5~1单位上述药物组合物,静脉注射给药,20-30分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法;特重病症患者,每日使用1~2单位上述药物组合物,中心静脉快速给药,10-15分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法。
本发明中所述的氨基酸无特别说明的均为左旋氨基酸。
本发明的有益效果:
本发明独创性的使用含有L-鸟氨酸、天冬氨酸、精氨酸的复方氨基酸注射液+大剂量B族维生素,视病情配合维生素C的冲击疗法,高效地打通MODS状态下机体的代谢途径,为挽救凝血障碍大出血濒死患者提供了经济有效的方法,该方法在国内外并无文献报道。
本发明中的含有L-鸟氨酸、天冬氨酸、精氨酸的复方氨基酸注射液+大剂量B族维生素冲击疗法治疗数百名急危重病患者,前后总蛋白(TP)、白蛋白(ALB)、总胆红素(TBIL)、间接胆红素(IBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)有显著下降变化,凝血功能、HB的上升、免疫功能的提高明显,球蛋白(GLB)、白/球(A/B)、直接胆红素(DBIL)没有显著变化。即含有L-鸟氨酸、天冬氨酸、精氨酸的复方氨基酸注射液联用大剂量B族维生素新疗法在危重病救治中的确能起到重要作用,对肝功能的恢复、凝血功能、HB的上升、免疫功能的提高有非常大的帮助。
在常规治疗的基础上,创新性的使用含有L-鸟氨酸、天冬氨酸、精氨酸的复方氨基酸注射液联用大剂量B族维生素的冲击疗法治疗:
1)有引起MODS的病因,感染及非感染性因素(严重创伤、重型胰腺炎、大手术、心肺复苏、病理产科等)出现凝血功能异常而导致出血的患者。
2)肝功能不正常并发凝血功能异常而导致出血的患者。
3)其它疾病并发凝血功能异常而导致出血的患者。对于严重创伤造成的机体代谢紊乱,特别是MODS状态下的多器官衰竭也有辅助疗效。
具体实施方式
以下通过实施例对本发明作进一步的阐述。
实施例1:临床治疗情况统计
一、病例入选标准:
(1)有引起MODS的病因,感染及非感染性因素(严重创伤、重型胰腺炎、大手术、心肺复苏、病理产科等)出现凝血功能异常而导致出血的患者。
(2)上述因素发生24小时后按Marshall标准(表1)单一器官损伤积分≥1分为系统、器官功能障碍(SOD),≥3分为系统、器官功能衰竭(SOF)。
(3)年龄18~86岁。
(4)MODS及肝功能异常时出现凝血功能异常而导致出血的患者。
本发明中,轻度患者、重度患者、特重病症患者的判断标准为:采用加拿大Marshall教授1995年的评分标准,得分越高,病情越严重,见表1、2。
表1MODS评分标准(Marshall 1995年)
注:PAR(压力调整后心率)=心率×右心房(中心静脉)压/平均血压
结合表1、2,轻度患者为MODS评分0~1级、重度患者为MODS评分2~3级、特重病症患者为MODS评分4级,并根据失血性休克的表征辅助区分轻、重、特重。
二、排除标准:
(1)治疗未超过24小时死亡或出院者;
(2)未能坚持系统治疗者。
三、凝血功能改善判断标准:
(1)治疗0,1,4,7,14,28天抽取静脉血15ml,3000转/分钟离心,分离血清,置低温冰箱保存,统一检测。
(2)PLT、D-Dimer、FDP、Fib、全血凝血时间(CT)全部检测。
(3)观察实际出血停止的时间。
(4)肝脏:ALT、AST、PT及凝血酶原活动度、TBIL、白蛋白、胆碱酯酶。
四、疗效判断标准:
1、无效:结合常规治疗无作用或凝血功能仅有轻度改善,不能缓解出血症状;
2、有效:轻度患者结合常规治疗凝血功能明显改善,1-9天内出血症状缓解;
3、显效:重度、特重症患者结合常规治疗凝血功能明显改善,1-5天内出血症状停止。
本发明所述的常规治疗是指针对出血患者使用止血药物,包括血小板、凝血酶原复合物、冷沉淀、血浆等一系列止血的方法,大血管破裂出血已通过外科手术止血。
五、治疗方法:
每个单位药物组合物含有:L-鸟氨酸0.5~8g,天冬氨酸1~5g,精氨酸3~10g,维生素B63-10g;
每个单位药物组合物还含有以下物质中的一种或多种:异亮氨酸3~10g,亮氨酸5~15g,赖氨酸3~10g,蛋氨酸0.5~3g,苯丙氨酸0.5~3g,苏氨酸3~10g,色氨酸0.5~3g,缬氨酸5~15g,组氨酸3~8g,甘氨酸3~8g,丙氨酸3~10g,脯氨酸3~8g,天冬酰胺0.1~3g,半胱氨酸0.1~3g,谷氨酸3~10g,丝氨酸0.5~5g,酪氨酸0.1~3g;B族维生素的用量分别是:VitB11~2mg,VitB21~2mg,VitB310~20mg,泛酸3~5mg,生物素0.1~0.2mg,叶酸0.1~0.4mg,VitB122~6μg;维生素C 1-3g。
上述物质可加入250ml~500ml 5%葡萄糖氯化钠注射液或0.9%氯化钠注射液(糖尿病患者采用0.9%氯化钠注射液)中。
轻度患者,结合常规治疗,每日使用1单位药物组合物,静脉输液给药,30分钟-6小时输液完毕,连续使用1-9天;
重度患者,结合常规治疗,每日使用0.5~1单位药物组合物,静脉注射给药,20-30分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法;
特重病症患者,结合常规治疗,每日使用1~2单位药物组合物,中心静脉快速给药,10-15分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法。
六、治疗效果:
选择轻度患者156例,重度患者68例,特重症患者21例,男169,女76,年龄为18~86岁,平均年龄57岁;
有效180例;显效55例;无效8例,排除病例2例。
实施例2:具体病例介绍
1、朱某,男,66岁。因胆囊结石,手术前凝血功能正常,手术进行胆囊切除术,手术操作顺利,手术中对血管和胆囊床的处理满意。手术后的当天上午一切正常,傍晚呕吐,后来腹腔引流管中出现血液,心跳加快,血压下降。于当晚再次手术,手术发现血管结扎线并未脱落,只是胆囊床有出血点,周围水肿,疑似呕吐后撕裂所致,将胆囊床仔细缝合,反复冲洗,经在手术台边的所有医护人员观察半小时,确认无出血后关腹,结束手术。当晚和第二天上午腹腔引流量不多,比较正常,但至傍晚腹腔引流量又明显增加,出血明显,进行第三次手术。打开腹腔后发现腹腔内并没有明显的出血点,只是肝脏、肝脏周围组织及后腹腔水肿明显,血液慢慢渗出,压迫止血、缝合止血和电凝止血等常规手段根本不起作用。于是,连续给病人使用了大量的止血药物,包括血小板、凝血酶原复合物、冷沉淀、血浆等,出血略有减少,但仍不断。在常规止血措施基础上,配合使用复方氨基酸注射液500ml(含有:L-鸟氨酸2.80g,天冬氨酸2.50g,精氨酸8.50g,异亮氨酸7.80g,亮氨酸12.50g,赖氨酸7.50g,蛋氨酸1.80g,苯丙氨酸1.60g,苏氨酸4.60g,组氨酸4.50g,甘氨酸5.50g,脯氨酸6.60g,天冬酰胺1.20g,半胱氨酸0.80g,谷氨酸5.90g,酪氨酸1.20g)+大剂量维生素B6冲击疗法救治(50支维生素B6(5g)和2支维生素C(2g)的250mL5%葡萄糖氯化钠注射液),静脉输液给药,30分钟输液完毕。半小时后,病人肝脏和周围的水肿有所消退,腹腔出血也有所减少。一小时后,出血更少了,关上了腹腔,结束了手术。术后病人顺利康复出院了。
2、方某,男,41岁。患者因肝硬化、门脉高压症、脾功能亢进、食道静脉破裂大出血四个月前行脾脏切除加门奇静脉断流术,手术后再次大出血,经过积极治疗病情稳定后出院。四天前洗澡后又发生大出血,血色素最底时4.8g,病情一度稳定后又大出血,经过输血输血浆及蛋白,止血药物等,患者血色素上升到7.3g,但出现大量腹水,肾功能不全,还有大量出血。根据病情,采用局部和全身治疗相结合的方法,患者采用免疫营养支持,采用改善微循环、拮抗炎性介质、促进酶代谢逐步恢复等治疗措施扼止住了患者危重状态进展。适当采用利尿措施,同时每日使用复方氨基酸注射液500mL(含有:L-鸟氨酸1.85g,天冬氨酸2.50g,精氨酸8.80g,异亮氨酸8.80g,亮氨酸13.60g,赖氨酸7.51g,苯丙氨酸1.60g,苏氨酸4.60g,色氨酸1.50g,缬氨酸10.60g,组氨酸4.70g,甘氨酸6.30g,丙氨酸8.30g,脯氨酸7.10g,天冬酰胺0.48g,谷氨酸5.70g,丝氨酸3.70g,酪氨酸0.67g)+维生素B68g(加入到250mL5%葡萄糖氯化钠注射液),静脉输液给药,2小时内输液完毕,连用4天,进行冲击疗法救治,患者病情已趋稳定,后出血停止,患者得救。
3、杨某,女,85岁。病例号752。广泛性脑梗塞,重度糖尿病,肺部严重感染致MODS,昏迷五天,经过免疫营养支持,采用改善微循环、拮抗炎性介质、促进酶代谢逐步恢复等治疗措施扼止患者危重状态进展的。每日使用含有复方氨基酸注射液500mL(含有:L-鸟氨酸4.50g,天冬氨酸2.80g,精氨酸8.50g,异亮氨酸7.50g,亮氨酸10.80g,赖氨酸8.50g,蛋氨酸1.60g,苯丙氨酸2.00g,苏氨酸4.60g,色氨酸1.50g,缬氨酸10.50g,组氨酸4.70g,甘氨酸6.30g,丙氨酸8.00g,脯氨酸6.50g,天冬酰胺0.60g,半胱氨酸0.80g,谷氨酸5.00g,丝氨酸3.50g,酪氨酸1.60g)+维生素B610g+维生素B11.5mg+维生素B21.5mg+维生素C 2g(维生素加入到250mL0.9%氯化钠注射液),静脉注射给药,30分钟注射完毕,连用2天,进行冲击疗法,短程大剂量山莨菪硷及地塞米松联合应用(各0.66mg/kg/每次,3次/日,连用3天);大剂量联合使用抗需氧菌和抗厌氧菌抗生素等,使得危重病患者杨某能够渡过MODS的打击,从而苏醒过来,继续按上述方案输液复方氨基酸注射液500ml+维生素B610g+维生素C 2g,3小时输液完毕,连续使用3天,患者病情好转。
4、李某,男,84岁。患者因慢性肾功能衰竭需要长期隔日透析,并有脑梗塞,高血压,重度糖尿病,因为肺部严重感染致MODS,胃肠道出现应激性溃疡出血而昏迷。拟采用抢救濒死伤员的关键性技术,即采用局部和全身治疗相结合的方法,每日使用复方氨基酸注射液500mL(含有:L-鸟氨酸3.5g,天冬氨酸2.50g,精氨酸8.80g,异亮氨酸8.80g,亮氨酸13.60g,赖氨酸7.51g,蛋氨酸1.20g,苯丙氨酸1.60g,苏氨酸4.60g,色氨酸1.50g,缬氨酸10.60g,组氨酸4.70g,甘氨酸6.30g,丙氨酸8.30g,脯氨酸7.10g,天冬酰胺0.48g,半胱氨酸0.59g,谷氨酸5.70g,丝氨酸3.70g,酪氨酸0.67g)+维生素B65g+维生素C 2g(维生素加入到250mL0.9%氯化钠注射液),静脉注射给药,30分钟注射完毕,连用3天,进行冲击疗法救治,取得了成功,应激性溃疡出血停止,患者苏醒了过来,生命体症平稳,继续按上述方案输注复方氨基酸注射液500ml+维生素B66g+维生素C 2g,4小时输液完毕,连续使用5天,患者病情好转。
实施例3:药物组合物制备例
一种药物组合物,其组分为含有5种氨基酸的复方氨基酸注射液(其中L-鸟氨酸含量为1.5g,L-天冬氨酸的含量为2.5g,L-精氨酸的含量为8.5g,L-丝氨酸的含量为3.8g,L-苏氨酸的含量为4.6g),Vit B68g。
实施例4:药物组合物制备例
一种药物组合物,其组分为复方氨基酸注射液500mL(含有:L-鸟氨酸3.5g,天冬氨酸2.50g,精氨酸8.80g,异亮氨酸8.80g,亮氨酸13.60g,赖氨酸7.51g,蛋氨酸1.20g,苯丙氨酸1.60g,苏氨酸4.60g,色氨酸1.50g,缬氨酸10.60g,组氨酸4.70g,甘氨酸6.30g,丙氨酸8.30g,脯氨酸7.10g,天冬酰胺0.48g,半胱氨酸0.59g,谷氨酸5.70g,丝氨酸3.70g,酪氨酸0.67g),Vit B63-10g,Vit C 1-3g,维生素加入到0.9%氯化钠注射液250mL。
实施例5:药物组合物制备例
一种药物组合物,其组分为复方氨基酸注射液500mL(含有:L-鸟氨酸4.5g,天冬氨酸2.80g,精氨酸8.30g,异亮氨酸6.50g,亮氨酸12.00g,赖氨酸7.50g,蛋氨酸1.60g,苯丙氨酸1.40g,色氨酸1.80g,缬氨酸10.60g,组氨酸4.80g,甘氨酸6.20g,丙氨酸8.50g,脯氨酸7.10g,天冬酰胺0.48g,谷氨酸5.70g,丝氨酸3.70g,酪氨酸0.67g),Vit B63-10g,VitB11~2mg,VitB21~2mg,VitB310~20mg,泛酸3~5mg,生物素0.1~0.2mg,叶酸0.1~0.4mg,VitB122~6μg;Vit C 1-3g,维生素加入到5%葡萄糖氯化钠注射液250mL中。
实施例6:药物组合物制备例
一种药物组合物,其组分为复方氨基酸注射液500mL(含有:L-鸟氨酸2.5g,天冬氨酸2.50g,精氨酸8.80g,异亮氨酸6.80g,亮氨酸11.50g,赖氨酸7.50g,蛋氨酸1.60g,苯丙氨酸1.30g,苏氨酸4.40g,色氨酸1.70g,组氨酸4.60g,甘氨酸6.30g,丙氨酸8.30g,脯氨酸6.20g,天冬酰胺0.60g,半胱氨酸0.80g,谷氨酸5.70g,丝氨酸3.70g,酪氨酸1.10g),VitB11~2mg,VitB21~2mg,Vit B63-10g,Vit C 1-3g,维生素加入到5%葡萄糖氯化钠注射液250mL。
Claims (6)
1.一种用于治疗凝血障碍出血的药物组合物,其特征是每单位该药物组合物中含有:L-鸟氨酸0.5~8g,天冬氨酸1~5g,精氨酸3~10g,维生素B63-10g。
2.根据权利要求1所述的药物组合物,其特征在于每单位该药物组合物中还含有下列物质中的一种或多种:异亮氨酸,亮氨酸,赖氨酸,蛋氨酸,苯丙氨酸,苏氨酸,色氨酸,缬氨酸,组氨酸,甘氨酸,丙氨酸,脯氨酸,天冬酰胺,半胱氨酸,谷氨酸,丝氨酸,酪氨酸,VitB1,VitB2,VitB3,泛酸,生物素,叶酸,VitB12,维生素C;
其中:氨基酸的用量分别是:异亮氨酸3~10g,亮氨酸5~15g,赖氨酸3~10g,蛋氨酸0.5~3g,苯丙氨酸0.5~3g,苏氨酸3~10g,色氨酸0.5~3g,缬氨酸5~15g,组氨酸3~8g,甘氨酸3~8g,丙氨酸3~10g,脯氨酸3~8g,天冬酰胺0.1~3g,半胱氨酸0.1~3g,谷氨酸3~10g,丝氨酸0.5~5g,酪氨酸0.1~3g;B族维生素的用量分别是:VitB11~2mg,VitB21~2mg,VitB310~20mg,泛酸3~5mg,生物素0.1~0.2mg,叶酸0.1~0.4mg,VitB122~6μg;维生素C 1-3g。
3.根据权利要求1所述的药物组合物,其特征在于该药物组合物还含有适量的5%葡萄糖氯化钠注射液或0.9%氯化钠注射液。
4.权利要求1、2或3所述的药物组合物在制备治疗凝血障碍出血的药物中的应用。
5.一种因凝血障碍而出血的患者的救治方法,其特征是在适当时间内输注权利要求1、2或3所述的药物组合物。
6.根据权利要求5所述的治疗方法,其特征在于轻度出血的患者每日使用0.5~1单位权利要求1、2或3所述的药物组合物,静脉输液给药,30分钟-6小时输液完毕,连续使用1-9天;
重度出血的患者,每日使用0.5~1单位权利要求1、2或3所述的药物组合物,静脉注射给药,20-30分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法;
特重度出血的患者,每日使用1~2单位权利要求1、2或3所述的药物组合物,中心静脉快速给药,10-15分钟注射完毕,连续使用1-5天,待症状改善后采用同上述轻度患者的治疗方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102484519A CN101912394B (zh) | 2010-08-06 | 2010-08-06 | 一种用于治疗凝血障碍出血的药物组合物及其用途 |
PL10855546T PL2601951T3 (pl) | 2010-08-06 | 2010-12-10 | Kompozycja farmaceutyczna do leczenia krwawienia spowodowanego przez zaburzenia krzepnięcia krwi i stosowanie tej kompozycji |
EP20100855546 EP2601951B1 (en) | 2010-08-06 | 2010-12-10 | Pharmaceutical composition for treating hemorrhage caused by blood clotting disorder and use thereof |
PT108555467T PT2601951E (pt) | 2010-08-06 | 2010-12-10 | Composição farmacêutica para o tratamento de hemorragia causada pelo distúrbio da coagulação sanguínea e sua utilização |
ES10855546.7T ES2538395T3 (es) | 2010-08-06 | 2010-12-10 | Composición farmacéutica para el tratamiento de hemorragia causada por coagulopatía y uso de la misma |
PCT/CN2010/079678 WO2012016408A1 (zh) | 2010-08-06 | 2010-12-10 | 用于治疗因凝血障碍而出血的药物组合物及其用途 |
US13/520,004 US8952040B2 (en) | 2010-08-06 | 2010-12-10 | Pharmaceutical composition for treating coagulation disorder hemorrhage and method using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102484519A CN101912394B (zh) | 2010-08-06 | 2010-08-06 | 一种用于治疗凝血障碍出血的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101912394A true CN101912394A (zh) | 2010-12-15 |
CN101912394B CN101912394B (zh) | 2013-11-06 |
Family
ID=43320146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102484519A Active CN101912394B (zh) | 2010-08-06 | 2010-08-06 | 一种用于治疗凝血障碍出血的药物组合物及其用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8952040B2 (zh) |
EP (1) | EP2601951B1 (zh) |
CN (1) | CN101912394B (zh) |
ES (1) | ES2538395T3 (zh) |
PL (1) | PL2601951T3 (zh) |
PT (1) | PT2601951E (zh) |
WO (1) | WO2012016408A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772407A (zh) * | 2012-08-01 | 2012-11-14 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
WO2017107863A1 (zh) * | 2015-12-21 | 2017-06-29 | 岳茂兴 | 一种用于治疗运动神经元病的组合物及其用途 |
CN107184582A (zh) * | 2016-12-14 | 2017-09-22 | 岳茂兴 | 一种用于治疗运动神经元病的组合物及其用途 |
CN110269851A (zh) * | 2019-06-03 | 2019-09-24 | 岳茂兴 | 一种用于治疗创伤性休克的药物组合物及其应用 |
CN111295187A (zh) * | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
CN111789867A (zh) * | 2020-08-27 | 2020-10-20 | 中国人民解放军军事科学院军事医学研究院 | 一种适用于提高血浆干粉功能的适配液 |
US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3084319A1 (en) | 2017-12-11 | 2019-06-20 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
CN110339206A (zh) * | 2019-07-30 | 2019-10-18 | 岳茂兴 | 一种用于治疗顽固性痤疮的药物组合物及其应用 |
US20220218640A1 (en) * | 2021-01-14 | 2022-07-14 | Rob Dickerman | Amino acid delivery system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879648A (zh) * | 2005-06-19 | 2006-12-20 | 青岛众智医药科技有限公司 | 一种多种维生素冻干制剂及其制备方法 |
CN101181289A (zh) * | 2007-11-28 | 2008-05-21 | 南京海陵中药制药工艺技术研究有限公司 | 一种13种复合维生素注射剂及其生产工艺 |
CN101439036A (zh) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | 一种含18种氨基酸的药物组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
CN1640396A (zh) | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | 一组新的药物组合物 |
US20090076111A1 (en) * | 2004-03-02 | 2009-03-19 | Lee Steve S | Methods for improving glycemic control in humans |
ITMI20052204A1 (it) * | 2005-11-18 | 2007-05-19 | Umberto Cornelli | Uso di colostro per la profilassi delle sindroni influenzali |
US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
-
2010
- 2010-08-06 CN CN2010102484519A patent/CN101912394B/zh active Active
- 2010-12-10 PL PL10855546T patent/PL2601951T3/pl unknown
- 2010-12-10 ES ES10855546.7T patent/ES2538395T3/es active Active
- 2010-12-10 WO PCT/CN2010/079678 patent/WO2012016408A1/zh active Application Filing
- 2010-12-10 EP EP20100855546 patent/EP2601951B1/en active Active
- 2010-12-10 US US13/520,004 patent/US8952040B2/en active Active
- 2010-12-10 PT PT108555467T patent/PT2601951E/pt unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879648A (zh) * | 2005-06-19 | 2006-12-20 | 青岛众智医药科技有限公司 | 一种多种维生素冻干制剂及其制备方法 |
CN101181289A (zh) * | 2007-11-28 | 2008-05-21 | 南京海陵中药制药工艺技术研究有限公司 | 一种13种复合维生素注射剂及其生产工艺 |
CN101439036A (zh) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | 一种含18种氨基酸的药物组合物 |
Non-Patent Citations (2)
Title |
---|
《伤残医学杂志》 20031231 岳茂兴 "四大一支持"综合冲击疗法在腹部外科疾病并发MODS时的临床应用 5-8 1-6 第11卷, 第1期 2 * |
《华夏医学》 20000229 钟荣 多器官功能不全综合征的治疗进展 117-118 1-6 第13卷, 第1期 2 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772407A (zh) * | 2012-08-01 | 2012-11-14 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
WO2014019268A1 (zh) * | 2012-08-01 | 2014-02-06 | Yue Maoxing | 一种促进神经损伤修复的药物组合物及其应用 |
CN102772407B (zh) * | 2012-08-01 | 2014-09-17 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
US20150335627A1 (en) * | 2012-08-01 | 2015-11-26 | Maoxing Yue | Pharmaceutical composition for promoting nerve injury restoration and application thereof |
US10537540B2 (en) * | 2012-08-01 | 2020-01-21 | Tongge Huang | Pharmaceutical composition for promoting nerve injury restoration and application thereof |
GB2561747A (en) * | 2015-12-21 | 2018-10-24 | Nanjing Jianrong Bio Tech Co Ltd | Composition for treating motor neuron diseases and use thereof |
WO2017107863A1 (zh) * | 2015-12-21 | 2017-06-29 | 岳茂兴 | 一种用于治疗运动神经元病的组合物及其用途 |
GB2561747B (en) * | 2015-12-21 | 2021-05-12 | Nanjing Jianrong Bio Tech Co Ltd | Composition for treating motor neuron diseases and use thereof |
CN107184582A (zh) * | 2016-12-14 | 2017-09-22 | 岳茂兴 | 一种用于治疗运动神经元病的组合物及其用途 |
US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
CN111295187A (zh) * | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
US11571404B2 (en) | 2017-08-14 | 2023-02-07 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
CN110269851A (zh) * | 2019-06-03 | 2019-09-24 | 岳茂兴 | 一种用于治疗创伤性休克的药物组合物及其应用 |
CN111789867A (zh) * | 2020-08-27 | 2020-10-20 | 中国人民解放军军事科学院军事医学研究院 | 一种适用于提高血浆干粉功能的适配液 |
Also Published As
Publication number | Publication date |
---|---|
US20130143836A1 (en) | 2013-06-06 |
PT2601951E (pt) | 2015-07-07 |
CN101912394B (zh) | 2013-11-06 |
EP2601951A1 (en) | 2013-06-12 |
EP2601951A4 (en) | 2014-01-01 |
ES2538395T3 (es) | 2015-06-19 |
EP2601951B1 (en) | 2015-04-29 |
WO2012016408A1 (zh) | 2012-02-09 |
US8952040B2 (en) | 2015-02-10 |
PL2601951T3 (pl) | 2015-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912394B (zh) | 一种用于治疗凝血障碍出血的药物组合物及其用途 | |
AU652992B2 (en) | Method and composition for treating reperfusion injury | |
AP1185A (en) | Novel pharmaceutical composition for the use in emergency treatment and preparation method thereof. | |
JPH09500366A (ja) | 固形腫瘍及び他の疾患の治療のための薬剤の治療効果を改良する方法 | |
US20060127387A1 (en) | Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions | |
WO2003063780A2 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
CN109200279A (zh) | 一种溶解血栓、抗血凝的药物组合物 | |
CN1403156A (zh) | 人尿激肽原酶在制备治疗和预防脑梗塞药物中的应用 | |
Elman | ACUTE PROTEIN DEFICIENCY (HYPOPROTEINEMIA) IN SURGICAL SHOCK: DUE TO SEVERE HEMORRHAGE AND IN BURNS, INTESTINAL OBSTRUCTION AND GENERAL PERITONITIS, WITH SPECIAL REFERENCE TO THE USE OF PLASMA AND HYDROLIZED PROTEIN | |
PT91584B (pt) | Processo para a preparacao de uma composicao farmaceutica util para imunossupressao contendo um inibidor-activador de plasminogenio (pai-2) | |
Comens | Manganese depletion as an etiological factor in hydralazine disease | |
CN1218747C (zh) | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 | |
Cope | The chemical aspects of burn treatment | |
CN101024073A (zh) | 人尿激肽原酶在制备治疗和/或预防高血压合并脑梗塞药物中的应用 | |
CN100368017C (zh) | 一种具有促凝血作用的复方生物组分及其药物制剂 | |
Obeagu et al. | EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH) ISSN: 2992-4081© EEJPH Publications Volume 4 Issue 1 2023 Protamine Sulphate: An Antidote for Bleeding caused by Heparin | |
Engelberg | HEPARIN IN ACUTE MYOCARDIAL INFARCTION—Observations Indicating the Potential Advantages of Using It as the Sole Anticoagulant in Therapy | |
WO2005077405A1 (en) | Compositions and methods for the treatment of cancer by systemic elevation of lactate and consequent depletion of arginine | |
Tytgat et al. | Experience with exchange transfusion in the treatment of hepatic coma | |
US20160082051A1 (en) | Use of sea cucumber glycosaminoglycan in preparing medicine for prevention and treatment of thromboembolic disease | |
JPH07316072A (ja) | 妊娠中毒症治療剤 | |
WO2006047949A1 (en) | The use of human urinary kallidinogenase for the manufacture of a medicine for the treatment of acute coronary syndromes | |
Sari et al. | A Deep Dive into the Role of Hyperbaric Oxygen Therapy in Enhancing Burn Wound Healing | |
Pieper et al. | Altered bleeding time associated with ibuprofen and zidovudine use | |
RU2165763C1 (ru) | Способ иммунокорригирующей терапии заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151113 Address after: 36, 210000, Villa Magnolia, Yuhuatai District, Jiangsu, Nanjing 104 Patentee after: Huang Tongge Address before: 100101 Beijing city Chaoyang District Anxiang Road No. 9 Patentee before: Yue Maoxing Patentee before: Wan Honggui Patentee before: Huang Tongge |